Skip to content

Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow

Treatment of Stage 3 Osteonecrosis of the Femoral Head by Autologous Transplantation of Bone Marrow Cells: a Randomized, Controlled Double Blind Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01544712
Enrollment
50
Registered
2012-03-06
Start date
2004-08-31
Completion date
2010-09-30
Last updated
2012-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Traumatic Osteonecrosis of the Femoral Head (Hip)

Keywords

osteonecrosis, cell-based therapy, bone marrow, mesenchymal stem cell, hip, core decompression

Brief summary

In stage 3 Osteonecrosis (ON) of the femoral head, a beneficial effect of bone marrow grafting was reported with a reduction of the functional evolution and the necessity of a total prosthesis placement in a non-controlled retrospective trial. Based on this experience, the investigators would like to start a randomized controlled double blind study on the effect of autologous implantation of autologous bone marrow cells into the necrotic lesion of stage 3 ON of the femoral head.

Interventions

PROCEDUREcore decompression with autologous bone marrow implantation

core biopsy with injection of 40 ml concentrated autologous bone marrow.

PROCEDUREcore decompression of the femoral head

core biopsy with injection of 40 ml saline solution in place of bone marrow.

Sponsors

University of Liege
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. patients who have a non traumatic ON of the femoral head 2. Stage 3 ON (subchondral fracture). 3. Age \> 18 years 4. Be able and willing to participate in the study

Exclusion criteria

1. evidence of malignant disorder in the past five years 2. Patient unable to undergo a MRI. 3. Patient who is positive for an HIV, hepatitis B or C infection.

Design outcomes

Primary

MeasureTime frameDescription
reduction of total prosthesis24, 60 monthsNeed to undergo a surgical treatment total prosthesis

Secondary

MeasureTime frameDescription
Pain reduction24, 60 monthsVisual analogue scale
functional status24, 60 monthsLequesne and WOMAC scores

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026